IL162111A0 - Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo - Google Patents

Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo

Info

Publication number
IL162111A0
IL162111A0 IL16211101A IL16211101A IL162111A0 IL 162111 A0 IL162111 A0 IL 162111A0 IL 16211101 A IL16211101 A IL 16211101A IL 16211101 A IL16211101 A IL 16211101A IL 162111 A0 IL162111 A0 IL 162111A0
Authority
IL
Israel
Prior art keywords
heterologo
generation
production
precursor lymphocytes
modified vertebrate
Prior art date
Application number
IL16211101A
Other languages
English (en)
Original Assignee
4Antibody Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 4Antibody Ag filed Critical 4Antibody Ag
Publication of IL162111A0 publication Critical patent/IL162111A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0635—B lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/022—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from an adenovirus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • C12N2799/027—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a retrovirus

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Cell Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Hematology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
IL16211101A 2001-12-22 2001-12-22 Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo IL162111A0 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/EP2001/015303 WO2003068819A1 (en) 2001-12-22 2001-12-22 Method for the generation of genetically modified vertebrate precursor lymphocytes and use thereof for the production of heterologous binding proteins

Publications (1)

Publication Number Publication Date
IL162111A0 true IL162111A0 (en) 2005-11-20

Family

ID=27675551

Family Applications (2)

Application Number Title Priority Date Filing Date
IL16211101A IL162111A0 (en) 2001-12-22 2001-12-22 Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
IL162111A IL162111A (en) 2001-12-22 2004-05-20 Method for the generation of vertebrate lymphocytes and use thereof for the production of binding proteins or functional fragment(s) thereof

Family Applications After (1)

Application Number Title Priority Date Filing Date
IL162111A IL162111A (en) 2001-12-22 2004-05-20 Method for the generation of vertebrate lymphocytes and use thereof for the production of binding proteins or functional fragment(s) thereof

Country Status (8)

Country Link
US (2) US7741077B2 (ja)
JP (1) JP4238138B2 (ja)
CN (1) CN100360565C (ja)
AU (1) AU2002226390B2 (ja)
CA (1) CA2471392A1 (ja)
IL (2) IL162111A0 (ja)
NZ (1) NZ534205A (ja)
WO (1) WO2003068819A1 (ja)

Families Citing this family (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1568765A1 (en) * 2004-02-23 2005-08-31 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Method for genetic diversification in gene conversion active cells
WO2006072803A2 (en) * 2005-01-10 2006-07-13 Medical Research Council Antibody
WO2007060864A1 (ja) * 2005-11-24 2007-05-31 National University Corporation NARA Institute of Science and Technology 増殖と分化の制御可能な抗体産生前駆ｂ細胞
PT2540820T (pt) 2005-12-09 2018-03-02 Academisch Medisch Centrum Bij De Univ Van Amsterdam Meios e métodos para influenciar a establidade de células produtoras de anticorpos
WO2007067032A1 (en) 2005-12-09 2007-06-14 Academisch Medisch Cemtrum Bij De Universiteit Van Amsterdam Means and methods for influencing the stability of cells
US10155038B2 (en) 2007-02-02 2018-12-18 Yale University Cells prepared by transient transfection and methods of use thereof
US9249423B2 (en) 2007-02-02 2016-02-02 Yale University Method of de-differentiating and re-differentiating somatic cells using RNA
US8859229B2 (en) * 2007-02-02 2014-10-14 Yale University Transient transfection with RNA
NZ579010A (en) * 2007-02-20 2012-03-30 Anaptysbio Inc Somatic hypermutation systems
JP5537420B2 (ja) 2007-05-31 2014-07-02 ユニヴァーシティ オブ ワシントン 標的遺伝子の誘導性変異誘発
AU2008284015B2 (en) 2007-08-03 2014-05-15 Musc Foundation For Research Development Human monoclonal antibodies and methods for producing the same
EP2098536A1 (en) 2008-03-05 2009-09-09 4-Antibody AG Isolation and identification of antigen- or ligand-specific binding proteins
WO2010027062A1 (ja) * 2008-09-04 2010-03-11 独立行政法人理化学研究所 B細胞由来iPS細胞およびその用途
EP2358868B1 (en) * 2008-11-21 2014-11-12 California Institute of Technology In vitro human b lymphopoiesis culture system
AU2010271583B2 (en) 2009-07-15 2015-02-12 Kling Biotherapeutics B.V. Means and methods for producing high affinity antibodies
AU2010334809C1 (en) 2009-12-23 2015-02-26 Agenus Inc. Binding members for human cytomegalovirus
US9074223B2 (en) * 2010-01-08 2015-07-07 Immusoft Corporation Vectors and methods for transducing B cells
KR101667088B1 (ko) * 2010-02-12 2016-10-17 니토 보세키 가부시기가이샤 Ｋｕ86 와 이의 자가항체와의 복합체의 면역 측정 방법, 여기에 사용되는 키트 및 이를 이용한 암판정 방법
BR112013004266A8 (pt) 2010-08-23 2018-01-02 Univ Texas anticorpos anti-ox40 e métodos de uso dos mesmos.
HUE033141T2 (en) 2010-12-02 2017-11-28 Aimm Therapeutics Bv Instruments and methods for producing high affinity antibodies
CN102229960B (zh) * 2011-06-03 2013-04-03 中国科学院微生物研究所 小鼠白血病病毒转化骨髓细胞建立细胞系的方法及其应用
KR102542272B1 (ko) 2011-10-28 2023-06-13 리제너론 파아마슈티컬스, 인크. 유전자 변형된 ｔ 세포 수용체 마우스
US8962315B2 (en) 2011-12-22 2015-02-24 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including at least one endogenous gene expressing at least one endogenous membrane immunoglobulin reactive to a first antigen and including at least one exogenously incorporated nucleic acid expressing at least one exogenous secreted immunoglobulin reactive to a second antigen
US9175072B2 (en) * 2011-12-22 2015-11-03 Elwha Llc Compositions and methods including recombinant B lymphocyte cell line including an exogenously incorporated nucleic acid expressing an exogenous membrane immunoglobulin reactive to a first antigen and including an endogenous gene expressing an endogenous secreted immunoglobulin reactive to a second antigen
US10233424B2 (en) 2011-12-22 2019-03-19 Elwha Llc Compositions and methods including cytotoxic B lymphocyte cell line expressing exogenous membrane immunoglobulin different from secreted immunoglobulin
US10745468B2 (en) 2011-12-22 2020-08-18 Kota Biotherapeutics, Llc Compositions and methods for modified B cells expressing reassigned biological agents
DK2840892T3 (en) * 2013-02-20 2018-07-23 Regeneron Pharma Non-human animals with modified heavy chain immunoglobulin sequences
CN103571796B (zh) * 2013-11-15 2015-04-29 中国农业科学院哈尔滨兽医研究所 鸡白介素-10单克隆抗体及其制备方法和应用
WO2015115892A1 (en) 2014-01-31 2015-08-06 Aimm Therapeutics B.V. Means and methods for producing stable antibodies
US20170058029A1 (en) * 2014-05-02 2017-03-02 Chiome Bioscience Inc. Human antibody-producing cell
US10793642B2 (en) 2014-12-11 2020-10-06 Inbiomotion S.L. Binding members for human c-MAF
ES2959608T3 (es) * 2015-04-03 2024-02-27 Dana Farber Cancer Inst Inc Composición y métodos de edición del genoma de células B
HRP20231039T1 (hr) 2015-04-06 2023-12-22 Regeneron Pharmaceuticals, Inc. Imunosni odgovori posredovani humaniziranim t stanicama kod ne-humanih životinja
EP3320099B1 (en) * 2015-07-09 2023-09-13 Institut National de la Santé et de la Recherche Médicale (INSERM) Lentiviral vector expressing membrane-anchored or secreted antibody
WO2017025871A1 (en) 2015-08-07 2017-02-16 Glaxosmithkline Intellectual Property Development Limited Combination therapy comprising anti ctla-4 antibodies
KR20180042449A (ko) * 2015-09-15 2018-04-25 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 T 세포 수용체(tcr) 결합 항체 및 이의 용도
US11377637B2 (en) 2016-04-15 2022-07-05 Memorial Sloan Kettering Cancer Center Transgenic T cell and chimeric antigen receptor T cell compositions and related methods
EP3469069A4 (en) 2016-06-10 2020-01-22 Kota Biotherapeutics, LLC COMPOSITIONS AND METHODS COMPRISING A B LYMPHOCYTE CELL LINE EXPRESSING A MEMBRANE IMMUNOGLOBULIN DIFFERENT FROM A SECRETED IMMUNOGLOBULIN AND CYTOLYTIC FUNCTION
EP3494140A1 (en) 2016-08-04 2019-06-12 GlaxoSmithKline Intellectual Property Development Ltd Anti-icos and anti-pd-1 antibody combination therapy
EP3548068A1 (en) 2016-12-01 2019-10-09 GlaxoSmithKline Intellectual Property Development Limited Combination therapy
BR112019011370A2 (pt) 2016-12-01 2019-10-15 Glaxosmithkline Ip Dev Ltd terapia de combinação
EP3635011A1 (en) 2017-06-09 2020-04-15 GlaxoSmithKline Intellectual Property Development Limited Combination therapy with icos agonist and ox40 agonist to treat cancer
CN110831971A (zh) 2017-06-09 2020-02-21 葛兰素史克知识产权开发有限公司 用icos激动剂和ox40激动剂治疗癌症的组合疗法

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5169939A (en) * 1985-05-21 1992-12-08 Massachusetts Institute Of Technology & Pres. & Fellows Of Harvard College Chimeric antibodies
US6051225A (en) * 1988-10-19 2000-04-18 The Dow Chemical Company Family of high affinity, modified antibodies for cancer treatment
EP1690935A3 (en) 1990-01-12 2008-07-30 Abgenix, Inc. Generation of xenogeneic antibodies
US5622853A (en) 1990-05-01 1997-04-22 Becton Dickinson And Company T lymphocyte precursor
DK0585287T3 (da) 1990-07-10 2000-04-17 Cambridge Antibody Tech Fremgangsmåde til fremstilling af specifikke bindingsparelementer
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
KR100272077B1 (ko) * 1990-08-29 2000-11-15 젠팜인터내셔날,인코포레이티드 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물
US6300129B1 (en) * 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0605522B1 (en) 1991-09-23 1999-06-23 Medical Research Council Methods for the production of humanized antibodies
JPH05184386A (ja) 1991-12-27 1993-07-27 Sumitomo Chem Co Ltd 改変抗体及び改変抗体を産生する組み換え体
GB9423085D0 (en) 1994-11-16 1995-01-04 Stringer Bradley M J Targeted T lymphocytes
US20040016007A1 (en) * 2000-05-15 2004-01-22 Sonoko Habu Chimeric mouse having immunity constructed by using human cd34-positive cells and use thereof
US20050196755A1 (en) 2000-11-17 2005-09-08 Maurice Zauderer In vitro methods of producing and identifying immunoglobulin molecules in eukaryotic cells

Also Published As

Publication number Publication date
CN100360565C (zh) 2008-01-09
JP4238138B2 (ja) 2009-03-11
AU2002226390A1 (en) 2003-09-04
US7741077B2 (en) 2010-06-22
JP2005525800A (ja) 2005-09-02
WO2003068819A1 (en) 2003-08-21
CN1633448A (zh) 2005-06-29
NZ534205A (en) 2006-04-28
US20060052585A1 (en) 2006-03-09
AU2002226390B2 (en) 2007-11-15
CA2471392A1 (en) 2003-08-21
US20110059056A1 (en) 2011-03-10
IL162111A (en) 2009-07-20

Similar Documents

Publication Publication Date Title
IL162111A0 (en) Method for the generation of generically modified vertebrate precursor lymphocytes and use thereof for the production of heterologo
GB2347938B (en) Production method for hydrate and device for producing the same
AU2002249256A1 (en) Apparatus and process for the production of hydrogen
HK1082393A1 (en) Toothbrush and method for producing the same
EP1428795A4 (en) SILSESQUIOXANDERIVATE AND METHOD FOR THE PRODUCTION THEREOF
EP1535657A4 (en) MODIFIED SUBSTRATE AND METHOD FOR PRODUCING MODIFIED SUBSTRATE
EP1530814A4 (en) CERAMIC ANODES AND PROCESS FOR PRODUCING THESE ANODES
AU2002233670A1 (en) Process for producing perfluorocarbons and use thereof
AU2003281180A1 (en) Porous semiconductor and process for producing the same
AU7265400A (en) Method for the production of otoplastics and corresponding otoplastic
SG91948A1 (en) Manufacturing method of multilayer substrate and multilayer substrate produced by the manufacturing method
AU2003248074A8 (en) Composite nanoparticle and process for producing the same
AU2003261940A8 (en) Acicular silicon crystal and process for producing the same
AU2003291166A8 (en) Fumed metal oxide particles and process for producing the same
GB2386929B (en) Plain bearing and process for producing the same
HUP0401200A3 (en) Pharmaceutical compositiuons containing terbinafin and process for producing them
EP1433833A4 (en) INDUSTRIAL OIL AND PROCESS FOR PREPARING THE SAME
AU2003304246A8 (en) Method of forming nanostructures on ceramics and the ceramics formed
EP1651018A4 (en) SUBSTRATE AND METHOD FOR PRODUCING THE SAME
HK1085304A1 (en) Superconductor and method of producing the same
IL157474A0 (en) Method for producing a scintillator ceramic and use of the scintillator ceramic
EP1484622A4 (en) PRISM AND CORRESPONDING MANUFACTURING PROCEDURE
EP1568655A4 (en) MICROMACHINE AND PROCESS FOR PRODUCING THE SAME
IL143810A0 (en) Prophylactic article useful for both protection and diagnosis and method for use and production thereof
EP1516668A4 (en) HIGHLY ACTIVE PHOTOCATALYST AND PROCESS FOR PRODUCING THE SAME